TrialNature communications2025

The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial.

Jaume Mora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.